Dr. Michael Diem Steps Down from Board of Directors

Malvern, PA, March 7, 2023 – Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on...

Venatorx Pharmaceuticals announced two organizational changes: the retirement of its Chief Medical Officer, Timothy Henkel, M.D., Ph.D., and the step-down of Vincent Milano from the Board of Directors. Dr. Henkel will continue to serve as a strategic advisor to the company.

We presented new data during IDWeek 2022 for our novel investigational antibiotic cefepime-taniborbactam, including two oral presentations showcasing cefepime-taniborbactam and highlighting the safety and efficacy results from our recently completed pivotal Phase 3 complicated urinary tract infection clinical trial, CERTAIN-1.

We are excited to present new data at IDWeek 2022, October 19-23, 2022, in Washington, DC for our novel antibiotic cefepime-taniborbactam, including 2 oral presentations showcasing cefepime-taniborbactam and highlighting the safety and efficacy results from our recently completed pivotal Phase 3 complicated urinary tract infection (cUTI) clinical trial, CERTAIN-1.

We are honored to be selected by BARDA for Project BioShield. We are confident that cefepime-taniborbactam is extremely well-positioned to help address potential public health emergencies as increasing antibiotic multi-drug resistant infections continue to represent a global threat.

Venatorx is excited to be a part of this significant collaborative initiative that will enhance and centralize access to high-quality AMR surveillance data across multiple datasets around the globe. Vivli’s AMR Register is vital to support educational and scientific communications on the AMR burden and emerging resistance, as well as global public health at large.

Venatorx Pharmaceuticals announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.

Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.